HDL Mimetics Infusion and Regression of Atherosclerosis: Is It Still Considered a Valid Therapeutic Option?

about

HDL Mimetics Infusion and Regression of Atherosclerosis: Is It Still Considered a Valid Therapeutic Option?

Item

http://www.wikidata.org/entity/Q55257404

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

HDL Mimetics Infusion and Regr ...... ed a Valid Therapeutic Option?

@en

HDL Mimetics Infusion and Regr ...... ed a Valid Therapeutic Option?

@nl

type

Item

label

HDL Mimetics Infusion and Regr ...... ed a Valid Therapeutic Option?

@en

HDL Mimetics Infusion and Regr ...... ed a Valid Therapeutic Option?

@nl

prefLabel

HDL Mimetics Infusion and Regr ...... ed a Valid Therapeutic Option?

@en

HDL Mimetics Infusion and Regr ...... ed a Valid Therapeutic Option?

@nl

P1476

HDL Mimetics Infusion and Regr ...... ed a Valid Therapeutic Option?

@en

P2093

I Karalis

http://www.w3.org/2001/XMLSchema#string

J W Jukema

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Executive Summary: Heart Disease and Stroke Statistics--2012 Update: A Report From the American Heart Association

A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease

Cholesterol efflux pathways regulate myelopoiesis: a potential link to altered macrophage function in atherosclerosis

Journey through cholesteryl ester transfer protein inhibition: from bench to bedside

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease

ApoA-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apoB transgenic mice

Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease

Effects of torcetrapib in patients at high risk for coronary events

Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study.

P2888

s11886-018-1004-9

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S11886-018-1004-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-06-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1105011095

http://www.w3.org/2001/XMLSchema#string

P698

29926215

http://www.w3.org/2001/XMLSchema#string

P921

lipid

atherosclerosis

polycyclic compound

coronary artery disease

P932

6010501

http://www.w3.org/2001/XMLSchema#string